Upregulation of GZMK, TREM2, and OR4D10 as Prognostic Biomarkers in Thyroid Cancer: A Pan-Cancer and TCGA Data Analysis

GZMK、TREM2 和 OR4D10 上调作为甲状腺癌预后生物标志物:一项泛癌和 TCGA 数据分析

阅读:1

Abstract

The study of gene anomalies linked to thyroid cancer is gaining more and more attention, and these molecular indicators can offer scholarly support for thyroid cancer diagnosis, therapy selection, and prognosis. Genotype-tissue expression pan-cancer data and The Cancer Genome Atlas (TCGA) were used to investigate the expression of GZMK, TREM2, and OR4D10. In order to assess the relationship between GZMK, TREM2, and OR4D10 expression and patient outcome, TCGA clinical survival data were used. We used the clusterProfiler R software tool to conduct enrichment analysis of GZMK, TREM2, and OR4D10. Moreover, TCGA database analysis was used to assess the relationship between immune cell infiltration and GZMK, TREM2, and OR4D10 expression. GZMK, TREM2, and OR4D10 were strongly expressed in several kinds of malignancies including thyroid cancer. Gene sets related to proliferation that are involved in leukocyte cell-cell adhesion and mononuclear cell differentiation were significantly correlated with high expression of GZMK, TREM2, and OR4D10. Additional investigation revealed a correlation between high T cell and DC (dendritic cell) infiltration scores and high expression of GZMK, TREM2, and OR4D10. According to our research, OR4D10, TREM2, and GZMK could all be genes associated with thyroid cancer.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。